In developing countries, multiresistance is more common (Old and Threlfall, 1998).
Traditionally choramphenicol is the first-line agent for the treatment of typhoid and remains an appropriate treatment for typhoid in areas where the bacterium is still susceptible and resources for drug expenditure are few.